Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Food Scene
Community Directory
Community Service
Restaurant Guide
Rescue Me
Other
Specials
Entertainment Now
Spring Wellness
Home & Garden
Home Improvement
Home & Realty
Horizons
Outdoor Guide
Progress
Women
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Services
2022 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cellectis S.A. ADR
(NQ:
CLLS
)
2.040
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 24, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
50,253
Open
2.020
Bid (Size)
2.020 (19)
Ask (Size)
2.060 (8)
Prev. Close
2.040
Today's Range
1.980 - 2.090
52wk Range
1.770 - 5.040
Shares Outstanding
45,484,310
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
March 14, 2023
From
Cellectis Inc.
Via
Globe NewsWire
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 08, 2023
From
Cellectis Inc.
Via
Globe NewsWire
Performance
YTD
-10.13%
-10.13%
1 Month
-9.93%
-9.93%
3 Month
+2.51%
+2.51%
6 Month
-16.39%
-16.39%
1 Year
-56.03%
-56.03%
More News
Read More
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
March 06, 2023
From
Cellectis Inc.
Via
Globe NewsWire
Earnings Scheduled For March 8, 2023
March 08, 2023
Via
Benzinga
A Preview Of Cellectis's Earnings
March 07, 2023
Via
Benzinga
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
March 01, 2023
From
Cellectis Inc.
Via
Globe NewsWire
There's a Lot of Upside For Emerging Gene-Editing Companies
February 21, 2023
Via
MarketBeat
Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares
February 07, 2023
From
Cellectis Inc.
Via
Globe NewsWire
12 Health Care Stocks Moving In Friday's Intraday Session
February 03, 2023
Via
Benzinga
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
February 03, 2023
From
Cellectis Inc.
Via
Globe NewsWire
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 03, 2023
Via
Benzinga
Cellectis Announces Pricing of Follow-On Offering
February 03, 2023
From
Cellectis Inc.
Via
Globe NewsWire
12 Health Care Stocks Moving In Thursday's After-Market Session
February 02, 2023
Via
Benzinga
Cellectis Announces Launch of Follow-On Offering
February 02, 2023
From
Cellectis Inc.
Via
Globe NewsWire
7 CRISPR Stocks With the Best Long-Term Potential
January 30, 2023
Via
InvestorPlace
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
January 20, 2023
From
Cellectis Inc.
Via
Globe NewsWire
Why Is Calyxt (CLXT) Stock Up 140% Today?
January 17, 2023
Via
InvestorPlace
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
January 17, 2023
From
Cellectis Inc.
Via
Globe NewsWire
5 Most Expensive Health Care Stocks You Should Worry About
January 12, 2023
Via
Benzinga
Why Tesla Shares Are Trading Lower; Here Are 32 Stocks Moving Premarket
January 03, 2023
Via
Benzinga
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 03, 2023
Via
Benzinga
Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases
December 29, 2022
From
Cellectis Inc.
Via
Globe NewsWire
Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities
December 28, 2022
From
Cellectis Inc.
Via
Globe NewsWire
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
December 22, 2022
From
Cellectis Inc.
Via
Globe NewsWire
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?
December 22, 2022
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.